Simvastatin (Zocor) Therapy in Sickle Cell Disease

• ClinicalTrials.gov Identifier: NCT00508027
• Recruitment Status: Completed
• First Posted: July 27, 2007
• Results First Posted: August 16, 2013
• Last Update Posted: September 17, 2013
• Sponsor: UCSF Benioff Children's Hospital Oakland
• Collaborators: Department of Health and Human Services; FDA Office of Orphan Products Development
• Information provided by (Responsible Party): Carolyn Hoppe, UCSF Benioff Children's Hospital Oakland

Study Description

Brief Summary:

Recent clinical and experimental data indicate that statins have effects beyond cholesterol lowering that may be beneficial in sickle cell disease by protecting the vascular endothelium. Statins have been shown to attenuate endothelial dysfunction through their anti-inflammatory, anti-oxidant and anti-thrombotic properties. This phase I/II dose-escalating trial is designed to assess the safety and potential clinical efficacy of oral simvastatin (Zocor)in adolescents and adults with sickle cell disease (SCD).

Condition or disease	Intervention/treatment	Phase
Sickle Cell Disease	Drug: Simvastatin	Phase 1; Phase 2

Detailed Description:

Although statins have been used extensively for their cholesterol-lowering effects, recent clinical and experimental data indicate that statins regulate yet other processes, many of which play a major role in sickle cell disease (SCD). Independent of their cholesterol-lowering effects, statins have been shown to prevent damage to blood vessels in several ways, through upregulation of endothelial nitric oxide (NO)and decreased inflammation. Numerous studies documenting the protective effects of statins, together with data showing the therapeutic role of NO in SCD, provide the basis for investigating the potential clinical benefit of simvastatin in SCD.

Data supporting the safety and tolerability of simvastatin in patients with SCD are now needed. For this phase I/II dose-escalation study of oral simvastatin in SCD, we propose the following specific aims:

1. To obtain preliminary efficacy data on the effects of oral simvastatin on plasma biomarkers of endothelial injury in patients with SCD, and
2. To assess the safety and tolerability of oral simvastatin in patients with SCD.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 42 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase I/II Study of Simvastatin (Zocor) Therapy in Sickle Cell Disease
• Study Start Date: June 2007
• Actual Primary Completion Date: December 2011
• Actual Study Completion Date: December 2011

Arms and Interventions

Arm	Intervention/treatment
Simvastatin, Dose Escalation; There are no arms in this study. Simvastatin will be given in a dose-escalating fashion to 3 sequential dosage groups (20 mg/day, 40 mg/day, 80 mg/day).	Drug: Simvastatin; Comparison of 3 dosages of simvastatin given in a dose-escalating fashion. 20 mg, 40 mg, or 80 mg PO QD x 21 days followed by a drug taper x 4 days.; Other Name: Zocor

Outcome Measures

Primary Outcome Measures :

1. Change in Total Cholesterol Level [ Time Frame: Baseline, 21 days ]
   Change in serum total cholesterol level after treatment with simvastatin
2. Change in Hemoglobin Level [ Time Frame: Baseline, 21 days ]
   Change in plasma hemoglobin (Hb) level after treatment with simvastatin
3. Change in Serum Creatine Kinase Levels [ Time Frame: Baseline, 21 days ]
   Change in serum creatine kinase (CK) levels after treatment with simvastatin
4. Change in Serum Alanine Transaminase (ALT) Levels [ Time Frame: Baseline, 21 days ]
   Change in serum alanine transaminase (ALT) after treatment with simvastatin
5. Change in Serum Creatinine Levels [ Time Frame: Baseline, 21 days ]
   Change in serum creatinine (Cr) levels after treatment with simvastatin

Other Outcome Measures:

1. Change in Plasma NOx Levels [ Time Frame: Baseline, 21 days ]
   Measurements of the levels of plasma nitric oxide metabolites (NOx), high sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), vascular cell adhesion molecule-1 (VCAM-1), tissue factor (TF) and vascular endothelial growth factor (VEGF)were performed before and after simvastatin treatment. Changes in mean plasma biomarker levels were assessed for each dose level; however, dose level 3 results were not analyzed, as only 2 subjects were enrolled in this dose group.
2. Change in Plasma Hs-CRP Levels [ Time Frame: Baseline, 21 days ]
   Change in plasma high sensitivity C-reactive protein levels in subjects treated with simvastatin
3. Change in Plasma IL-6 Levels [ Time Frame: Baseline, 21 days ]
   Change in plasma IL-6 level after treatment with simvastatin
4. Change in Plasma VEGF Levels [ Time Frame: Baseline, 21 days ]
   Change in plasma vascular endothelial adhesion molecule-1 levels after treatment with simvastatin
5. Change in Plasma VCAM1 Levels [ Time Frame: Baseline, 21 days ]
   Change in plasma vascular cellular adhesion molecule-1 levels after treatment with simvastatin
6. Change in Plasma TF Levels [ Time Frame: Baseline, 21 days ]
   Change in plasma tissue factor (TF) levels after treatment with simvastatin

Eligibility Criteria

• Ages Eligible for Study: 13 Years and older (Child, Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Established diagnosis of sickle cell disease (HbSS, SC or Sβ-thalassemia)
• Age greater than or equal to thirteen years
• Weight greater than or equal to 35 kg

Exclusion Criteria:

• Renal dysfunction (Serum Creatinine > 1.5 UNL)
• Hepatic dysfunction (ALT > 2X UNL)
• Pretreatment total cholesterol < 100 mg/dL or triglycerides < 30 mg/dL
• Pretreatment baseline creatine kinase >1X UNL (215 U/L)
• Pregnancy/lactation
• RBC transfusion in the last 30 days
• Vaso-Occlusive Event needing hospitalization in the past 30 days
• Treatment with any statin drugs within the past 30 days
• Treatment with drugs having known metabolic interactions with statin drugs (e.g. cytochrome P450 3A4 metabolism), including ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, azithromycin, niacin (nicotinic acid), digoxin, coumadin, sildenafil or amiodarone within the past 30 days
• Treatment (past or present) with amiodarone
• Musculoskeletal disorder associated with an elevated creatine kinase level
• Past or present history of substance abuse (alcohol, cocaine, amphetamines, heroin, PCP)
• Allergy to statins

Contacts and Locations

Locations

United States, California

Children's Hospital and Research Center Oakland

Oakland, California, United States, 94609

Sponsors and Collaborators

UCSF Benioff Children's Hospital Oakland

Department of Health and Human Services

FDA Office of Orphan Products Development

Investigators

• Principal Investigator: Carolyn C Hoppe, M.D.; UCSF Benioff Children's Hospital Oakland

More Information

Additional Information:

Children's Hospital and Research Center Oakland Official Website 

NHLBI Website - Sickle Cell Disease 

Medline Plus: Sickle Cell Anemia 

Publications of Results:

Hoppe C, Kuypers F, Larkin S, Hagar W, Vichinsky E, Styles L. A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. Br J Haematol. 2011 Jun;153(5):655-63. doi: 10.1111/j.1365-2141.2010.08480.x. Epub 2011 Apr 8.

Other Publications:

Hebbel RP. Extracorpuscular factors in the pathogenesis of sickle cell disease. Am J Pediatr Hematol Oncol. 1982 Fall;4(3):316-9.

Hebbel RP. Perspectives series: cell adhesion in vascular biology. Adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest. 1997 Jun 1;99(11):2561-4. Review.

Hebbel RP. Special issue of Microcirculation: examination of the vascular pathobiology of sickle cell anemia. Foreword. Microcirculation. 2004 Mar;11(2):99-100.

Kaul DK, Liu XD, Choong S, Belcher JD, Vercellotti GM, Hebbel RP. Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice. Am J Physiol Heart Circ Physiol. 2004 Jul;287(1):H293-301. Epub 2004 Mar 4.

Wood KC, Hebbel RP, Granger DN. Endothelial cell P-selectin mediates a proinflammatory and prothrombogenic phenotype in cerebral venules of sickle cell transgenic mice. Am J Physiol Heart Circ Physiol. 2004 May;286(5):H1608-14. Epub 2004 Jan 2.

Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood. 2000 Oct 1;96(7):2451-9.

Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyörälä K. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1999 Dec 13-27;159(22):2661-7.

Laufs U, Wassmann S, Hilgers S, Ribaudo N, Böhm M, Nickenig G. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol. 2001 Dec 1;88(11):1306-7.

Hebbel RP, Vercellotti GM. The endothelial biology of sickle cell disease. J Lab Clin Med. 1997 Mar;129(3):288-93. Review.

Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med. 1997 Nov 27;337(22):1584-90.

Solovey A, Gui L, Key NS, Hebbel RP. Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest. 1998 May 1;101(9):1899-904.

Reiter CD, Gladwin MT. An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy. Curr Opin Hematol. 2003 Mar;10(2):99-107. Review.

Gladwin MT, Crawford JH, Patel RP. The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation. Free Radic Biol Med. 2004 Mar 15;36(6):707-17. Review.

Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest. 2000 Aug;106(3):337-8.

Brown MD, Wick TM, Eckman JR. Activation of vascular endothelial cell adhesion molecule expression by sickle blood cells. Pediatr Pathol Mol Med. 2001 Jan-Feb;20(1):47-72.

Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001 Nov;21(11):1712-9. Review.

Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999 Dec;84(3):413-28. Review. Erratum in: Pharmacol Ther 2000 May;86(2):199.

• Responsible Party: Carolyn Hoppe, Associate Hematologist, UCSF Benioff Children's Hospital Oakland
• ClinicalTrials.gov Identifier: NCT00508027
• Other Study ID Numbers: 1R01FD003080-01A1 ( U.S. FDA Grant/Contract )
• First Posted: July 27, 2007
• Results First Posted: August 16, 2013
• Last Update Posted: September 17, 2013
• Last Verified: August 2013

Keywords provided by Carolyn Hoppe, UCSF Benioff Children's Hospital Oakland:

sickle cell disease; simvastatin; statin drugs; nitric oxide donors; vascular injury

Additional relevant MeSH terms:

Anemia, Sickle Cell; Anemia, Hemolytic, Congenital; Anemia, Hemolytic; Anemia; Hematologic Diseases; Hemoglobinopathies; Genetic Diseases, Inborn; Simvastatin; Anticholesteremic Agents; Hypolipidemic Agents; Antimetabolites; Molecular Mechanisms of Pharmacological Action; Lipid Regulating Agents; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Enzyme Inhibitors